Community Oncology Global Congress 2026
Donald Trump Nominates Heidi Overton as Next FDA Commissioner
From the Marathon 2024 to Olympus 2026: ELPIDA Climbs for Children with Cancer Around the World
ASCO 2026 Guideline: A Risk-Adapted Framework for Early HR-Positive, HER2-Negative Breast Cancer
ctDNA and MRD in NSCLC: Emerging Clinical Applications in the Immunotherapy Era
Pancreatic Cancer FDA Approval Following Landmark Trial Led by Dana-Farber
Giannis Mountzios: A New ESMO Guide for Thoracic Cancer Care
DART-PHASER: Daily Adaptive Salvage Radiotherapy in Prostate Cancer
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
